Claims for harm linked to Dupixent in Idaho

Idaho's rapidly growing population — fueled by migration from California, Washington, and Oregon — has expanded the state's Dupixent prescribing base to an estimated 14,000 patients since 2017. The Boise metropolitan area accounts for the majority of the state's dermatology and allergy prescriptions, with Saint Alphonsus and St. Luke's health systems providing primary specialty care. Idaho lacks an NCI-designated cancer center, and Dupixent patients developing CTCL symptoms are typically referred to the Huntsman Cancer Institute at the University of Utah in Salt Lake City for specialized cutaneous lymphoma evaluation. Idaho's Product Liability Reform Act provides a specific statutory framework for pharmaceutical claims, including a 2-year limitations period and potential statute of repose considerations.

For the overall process and updates, read the Claims for harm linked to Dupixent overview. This page covers the local information available for Idaho.